Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1)
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Rheumatology"
DOI: 10.1007/s10067-019-04863-0
Abstract: Introduction Although there is abundant evidence of vascular perturbation from studies of peripheral blood in systemic sclerosis (SSc), there are few data about the ability to use biomarkers of vascular injury and growth factors to… read more here.
Keywords: trial oral; trial; randomized controlled; oral treprostinil ... See more keywords
Inpatient Initiation of Oral Treprostinil in an Academic Medical System
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-020-06992-0
Abstract: Purpose Clinicians may transition patients on parenteral or inhaled prostacyclins to oral treprostinil for ease of use or to avoid adverse effects related to parenteral therapy. However, few data are available to guide these transitions… read more here.
Keywords: system; oral treprostinil; inpatient initiation; initiation oral ... See more keywords
TRANSITION FROM SELEXIPAG TO ORAL TREPROSTINIL IN A PATIENT WITH PULMONARY ARTERIAL HYPERTENSION
Sign Up to like & getrecommendations! Published in 2018 at "Chest"
DOI: 10.1016/j.chest.2018.08.923
Abstract: Prostacyclins are the mainstay treatment for patients with severe pulmonary arterial hypertension. This case highlights the transition from selexipag to oral treprostinil. Our patient improved both subjectively and objectively. Cardiac output and index, as measured… read more here.
Keywords: selexipag oral; oral treprostinil; arterial hypertension; pulmonary arterial ... See more keywords
Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medical economics"
DOI: 10.1080/13696998.2023.2204769
Abstract: BACKGROUND Pulmonary arterial hypertension (PAH), a rare vasculopathy progressively leading to right heart failure and death, is associated with considerable economic burden. Oral prostacyclin pathway agents (PPAs) like selexipag and treprostinil address an underlying PAH… read more here.
Keywords: oral treprostinil; treprostinil oral; oral selexipag; inhaled treprostinil ... See more keywords
An Event-driven Trial for Oral Treprostinil. Progress but Not the Holy Grail
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Respiratory and Critical Care Medicine"
DOI: 10.1164/rccm.201912-2431ed
Abstract: Finally, this study suffers from underpowering, as it includes just 102 samples, less than half of which are the preinvasive AIS/MIA lesions of interest. Atypical alveolar hyperplasia, a presumed precursor of AIS, was not studied.… read more here.
Keywords: oral treprostinil; driven trial; treprostinil progress; trial oral ... See more keywords
Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension
Sign Up to like & getrecommendations! Published in 2018 at "Pulmonary Circulation"
DOI: 10.1177/2045893217744512
Abstract: Oral treprostinil (TRE) is a prostacylin that is approved for the treatment of patients with pulmonary arterial hypertension (PAH). Dosing is approved for two or three times daily (t.i.d.); however, adverse effects, including gastrointestinal-related symptoms,… read more here.
Keywords: oral treprostinil; daily dose; times daily; hypertension ... See more keywords
Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension
Sign Up to like & getrecommendations! Published in 2018 at "Pulmonary Circulation"
DOI: 10.1177/2045894018797270
Abstract: Despite the increasing trends, reports on long-term follow-up are limited on transitioning from parenteral to oral treprostinil therapy in patients with pulmonary arterial hypertension (PAH). We investigated both the effectiveness of parenteral to oral treprostinil… read more here.
Keywords: oral treprostinil; transition; parenteral oral; transition transition ... See more keywords
Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
Sign Up to like & getrecommendations! Published in 2019 at "Pulmonary Circulation"
DOI: 10.1177/2045894019856471
Abstract: Treprostinil, a prostacyclin analogue, is approved for the treatment of pulmonary arterial hypertension (PAH) in adults. Transition from parenteral to oral treprostinil has been successfully accomplished in adults with PAH but not in children. In… read more here.
Keywords: therapy; oral treprostinil; transition; arterial hypertension ... See more keywords
Oral treprostinil use in children: a multicenter, observational experience
Sign Up to like & getrecommendations! Published in 2019 at "Pulmonary Circulation"
DOI: 10.1177/2045894019862138
Abstract: Pulmonary arterial hypertension is a progressive, incurable disease that occurs in adults and children alike. Therapeutic options for children are limited and infrequently described, including newer agents such as treprostinil, an oral prostanoid. Herein, we… read more here.
Keywords: oral treprostinil; treprostinil use; children multicenter; use children ... See more keywords
Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
Sign Up to like & getrecommendations! Published in 2020 at "Pulmonary Circulation"
DOI: 10.1177/2045894019898032
Abstract: Prostacyclins are the mainstay treatment for patients with severe pulmonary arterial hypertension. This case highlights the transition from selexipag to oral treprostinil. Our patient improved both subjectively and objectively. Cardiac output and index, as measured… read more here.
Keywords: selexipag oral; oral treprostinil; arterial hypertension; pulmonary arterial ... See more keywords